Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun;41(6):1186-1188.
doi: 10.1111/liv.14894.

Combined hepatocellular-cholangiocarcinoma - More questions than answers

Richard A Hubner  1 , Helen L Reeves  2 , Julien Edeline  3
Affiliations
Editorial

Combined hepatocellular-cholangiocarcinoma - More questions than answers

Richard A Hubner et al. Liver Int. 2021 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Kim EJ, Yoo C, Kang HJ, et al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int. 2021.
    1. European Association for the Study of the Liver. Electronic Address E E E, European Association for the Study of the L. Easl. Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
    1. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411-428.
    1. Rogers JE, Bolonesi RM, Rashid A, et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol. 2017;8: 347-351.
    1. Kobayashi S, Terashima T, Shiba S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci. 2018;109: 2549-2557.

LinkOut - more resources